Clinical Trial Update: Rituximab to Prevent Recurrence of Proteinuria [Phase 3]

View source ↗

Summary

Phase 3 trial update on rituximab to prevent recurrence of proteinuria in FSGS; the study was terminated with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis
• Proteinuria

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: George W. Burke | Conditions: FSGS, Proteinuria | Phase 3 | Status: TERMINATED | Results posted: 2018-09-20